Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin with GemOxD for Relapsed/Refractory Aggressive Lymphomas
NCT02181218Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of romidepsin in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL) and 1 more (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Maximum Tolerated Dose at 37 months. Started Feb 2015; status: completed.
02
Drugs
romidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)Hodgkin lymphoma (HL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02181218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181218.